Evaluation of Gyrolab™ and Meso-Scale Discovery platforms in the development of a clinical immunogenicity assay
J Collet, A Moreau et. al. NovImmune SA, Geneva, Switzerland
Comparative HCP Testing Using Traditional and Emerging Technologies
Martha Jackson, David Cirelli, Phoebe Baldus, Ned Mozier. BioTherapeutics Pharmaceutical Sciences, Analytical Research and Development, Pfizer, Andover, MA
High Throughput Process-related Impurity Testing Using a Gyrolab™ Workstation
Meletios Roussis, Eric Beard, Keshavamurthy Prakash, Robert Strouse and Michael Washabaugh. Analytical Biochemistry, MedImmune, Gaithersburg, MD 20878 USA
Gyrolab CHO-HCP kit panel simplifies HCP assay selection in bioprocess development
Gyros Protein Technologies offers a range of five ready-to-use kits to measure HCP impurities from Chinese Hamster Ovary cells (CHO), based on commercially available antibody preparations.
Development of residual host cell protein assays for recombinant microbial biopharmaceuticals
Katja Peiris and Daniel Schiwek, LCMD Analytical Development, Lonza AG, Switzerland
Capillary microsampling of liquid matrices. Better Science – Fewer Animals
New opportunities for collection and handling of extremely small volumes of biofluids – From early screen to late clinic. Ove Jonsson Global DMPK, AstraZeneca R&D, Södertälje, Sweden.
Quantitative Ligand Binding Assay for Determination of Antibody Drug Conjugate Using Gyrolab Immunoassay Platform
Aidong Wu, Tracey Clark, Chad Ray, Frank Barletta, Erick Kindt, Scott Fountain, Pfizer Global R&D, USA
One mouse one PK The magic of capillary microsampling and the Gyrolab assay platform
Sufyan Maqbool, Jo Goodman, David Fairman, Dominic Corkill, BSU & Bioanalytical Sciences, Clinical Pharmacology & DMPK (CPD) Ove Jonsson, Michael Spreadborough, Christopher Smith. MedImmune
Development and validation on a pharmacokinetic assay on Gyrolab platform for use in Phase II/III clinical studies
M. Dula, S. Fernando et. al. Morphotek Bioanalytical Dev.
A Simplified Process to Develop “Fit-for-Purpose” PK/PD Assays in Support of Early Drug Discovery Programs
Rong Liu, Renuka Pillutla, Binodh Desilva, Yan Zhang. BAS-Biologics, Bristol Myers Squibb, Princeton, NJ
A Generic Pharmacokinetic (PK)/ Toxicokinetic (TK) Assay Kit for Analysis of Biotherapeutic Antibodies in Sera from Several Species for Early-stage Development using Gyrolab™ Platforms
Ready to use Gyrolab Generic PK/TK kits streamlines evaluation of drug candidates for multiple programs using only nanoliter volumes and eliminates the time and resources needed for assay development and reagent screening.
Product quantification (IgG Titer) using an automated analytical platform–Gyrolab workstation
Lin Wang, Ph.D., Li Zhang, Fang Li and Eike Zimmermann,Ph.D. Boehringer Ingelheim, Fremont CA, USA